Compare Annaly Capital Management, Inc. (NLY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs GeneDx Holdings Corp — how do they compare? Annaly Capital Management, Inc. trades at $22.87 (market cap $16.63B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Annaly Capital Management, Inc. is far larger — about 9.2× GeneDx Holdings Corp's market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NLY | WGS | |
|---|---|---|
Market Cap | $16.63B | $1.80B |
Sector | Financials | Technology |
52-Week High | $24.40 | $167.51 |
52-Week Low | $19.96 | $34.51 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $1.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
